Effective silencing of EGFR with RNAi demonstrates non-EGFR dependent proliferation of glioma cells

International Journal of Oncology

Volumn 28, Issue 6, 2006, Pages 1531-1542

  Vollmann, Arabel ^a,c   Vornlocher, Hans Peter ^b   Stempfl, Thomas ^c   Brockhoff, Gero ^a   Apfel, Rainer ^d   Bogdahn, Ulrich ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b ALNYLAM PHARMACEUTICALS   (United States)

^c Center of Excellence for Fluorescent Bioanalysis   (Germany)

^d Teva Pharmaceuticals Germany GmbH   (Germany)

Author keywords

AG1478; Epidermal growth factor receptor; Gene expression analysis; Glioma; siRNA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; BRAIN TUMOR; CELL DIVISION; CELL LINE; CELL MOTION; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; GLIOMA; HUMAN; PATHOLOGY; POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE;

BRAIN NEOPLASMS; CELL DIVISION; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; TRANSFECTION;

EID: 33747099671     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.6.1531     Document Type: Article

References (58)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
2. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A and Schlessinger J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313: 144-147, 1985.
3. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR and Vogelstein B: Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84: 6899-6903, 1987.
4. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF and Collins VP: Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51: 2164-2172, 1991.
5. Frederick L, Wang XY, Eley G and James CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60: 1383-1387, 2000.
6. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
7. Hackel PO, Zwick E, Prenzel N and Ullrich A: Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 11: 184-189, 1999.
8. Prenzel N, Fischer OM, Streit S, Hart S and Ullrich A: The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8: 11-31, 2001.
9. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW and Burgess AW: Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284: 31-53, 2003.
10. Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ, Huang HJ and Cavanee WK: Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 61: 5349-5354, 2001. (Pubitemid 32694908)
11. Wakeling AE: Epidermal growth factor receptor tyrosine kinase inhibitors. Curr Opin Pharmacol 2: 382-387, 2002.
12. Halatsch ME, Schmidt U, Botefur IC, Holland JF and Ohnuma T: Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA. J Neurosurg 92: 297-305, 2000.
13. Sugawa N, Ueda S, Nakagawa Y, Nishino H, Nosaka K, Iwashima A and Kurimoto M: An antisense EGFR oligodeoxynucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas in vitro. J Neurooncol 39: 237-244, 1998.
14. Kretschmer-Kazemi Far R and Sczakiel G: The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res 31: 4417-4424, 2003.
15. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001.
16. Kittler R and Buchholz F: RNA interference: gene silencing in the fast lane. Semin Cancer Biol 13: 259-265, 2003.
17. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Rohl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M and Vornlocher HP: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178, 2004.
18. Harborth J, Elbashir SM, Bechert K, Tuschl T and Weber K: Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci 114: 4557-4565, 2001.
19. Bernhardt G, Reile H, Birnbock H, Spruss T and Schönenberger H: Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. J Cancer Res Clin Oncol 118: 35-43, 1992.
20. Blindt R, Bosserhoff AK, vom Dahl J, Hanrath P, Schror K, Hohlfeld T and Meyer-Kirchrath J: Activation of IP and EP(3) receptors alters cAMP-dependent cell migration. Eur J Pharmacol 444: 31-37, 2002.
21. Martinez-Lacaci I, De Santis M, Kannan S, Bianco C, Kim N, Wallace-Jones B, Wechselberger C, Ebert AD and Salomon DS: Regulation of heparin-binding EGF-like growth factor expression in Ha-ras transformed human mammary epithelial cells. J Cell Physiol 186: 233-242, 2001.
22. Unlu A and Leake RE: The effect of EGFR-related tyrosine kinase activity inhibition on the growth and invasion mechanisms of prostate carcinoma cell lines. Int J Biol Markers 18: 139-146, 2003.
23. Guerrero J, Santibanez JF, Gonzalez A and Martinez J: EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases. Exp Cell Res 292: 201-208, 2004.
24. Bhattacharya A, Lakka SS, Mohanam S, Boyd D and Rao JS: Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines. Clin Cancer Res 7: 267-276, 2001.
25. Chen P, Xie H, Sekar MC, Gupta K and Wells A: Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J Cell Biol 127: 847-857, 1994.
26. Berens ME, Rief MD, Shapiro JR, Haskett D, Giese A, Joy A and Coons SW: Proliferation and motility responses of primary and recurrent gliomas related to changes in epidermal growth factor receptor expression. J Neurooncol 27: 11-22, 1996.
27. Levitzki A and Gazit A: Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782-1788, 1995.
28. Chakravarti A, Chakladar A, Delaney MA, Latham DE and Loeffler JS: The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 62: 4307-4315, 2002.
29. Lal A, Glazer CA, Martinson HM, Friedman HS, Archer GE, Sampson JH and Riggins GJ: Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 62: 3335-3339, 2002.
30. Steinbach JP, Supra P, Huang HJ, Cavenee WK and Weller M: CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity. Brain Pathol 12: 12-20, 2002.
31. Lipson KE, Pang L, Huber LJ, Chen H, Tsai JM, Hirth P, Gazit A, Levitzki A and McMahon G: Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation. J Pharmacol Exp Ther 285: 844-852, 1998.
32. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A and Pazdur R: United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10: 1212-1218, 2004.
33. Shankar PP, Wei H, Davee SM and Funk JL: Parathyroid hormone-related protein is expressed by transformed and fetal human astrocytes and inhibits cell proliferation. Brain Res 868: 230-240, 2000.
34. Sweeney C, Fambrough D, Huard C, Diamonti AJ, Lander ES, Cantley LC and Carraway KL III: Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors. J Biol Chem 276: 22685-22698, 2001.
35. Kowanetz K, Husnjak K, Holler D, Kowanetz M, Soubeyran P, Hirsch D, Schmidt MH, Pavelic K, De Camilli P, Randazzo PA and Dikic I: CIN85 associates with multiple effectors controlling intracellular trafficking of EGF receptors. Mol Biol Cell 15: 3155-3166, 2004.
36. Swindle CS, Tran KT, Johnson TD, Banerjee P, Mayes AM, Griffith L and Wells A: Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol 154: 459-468, 2001.
37. Graham NA and Asthagiri AR: Epidermal growth factor-mediated T-cell factor/lymphoid enhancer factor transcriptional activity is essential but not sufficient for cell cycle progression in nontransformed mammary epithelial cells. J Biol Chem 279: 23517-23524, 2004.
38. Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, Taylor J and Hanash SM: Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 61: 6885-6891, 2001.
39. Van den Boom J, Wolter M, Kuick R, Misek DE, Youkilis AS, Wechsler DS, Sommer C, Reifenberger G and Hanash SM: Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 163: 1033-1043, 2003.
40. Taira T, Maeda J, Onishi T, Kitaura H, Yoshida S, Kato H, Ikeda M, Tamai K, Iguchi-Ariga SM and Ariga H: AMY-1, a novel C-MYC binding protein that stimulates transcription activity of C-MYC. Genes Cells 3: 549-565, 1998. (Pubitemid 28475324)
41. Yue S, Serra HG, Zoghbi HY and Orr HT: The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract. Hum Mol Genet 10: 25-30, 2001.
42. Pettersson M, Bessonova M, Gu HF, Groop LC and Jonsson JI: Characterization, chromosomal localization, and expression during hematopoietic differentiation of the gene encoding Arl6ip, ADP-ribosylation-like factor-6 interacting protein (ARL6). Genomics 68: 351-354, 2000.
43. Egidy G, Eberl LP, Valdenaire O, Irmler M, Majdi R, Diserens AC, Fontana A, Janzer RC, Pinet F and Juillerat-Jeanneret L: The endothelin system in human glioblastoma. Lab Invest 80: 1681-1689, 2000.
44. Vacca F, Bagnato A, Catt KJ and Tecce R: Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 60: 5310-5317, 2000.
45. Rajeevan MS, Ranamukhaarachchi DG, Vernon SD and Unger ER: Use of real-time quantitative PCR to validate the results of cDNA array and differential display PCR technologies. Methods 25: 443-451, 2001.
46. Eller JL, Longo SL, Hicklin DJ and Canute GW: Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery 51: 1005-1014, 2002.
47. Halatsch ME, Gehrke EE, Vougioukas VI, Botefur IC, A-Borhani F, Efferth T, Gebhart E, Domhof S, Schmidt U and Buchfelder M: Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. J Neurosurg 100: 523-533, 2004.
48. Stea B, Falsey R, Kislin K, Patel J, Glanzberg H, Carey S, Ambrad AA, Meuillet EJ and Martinez JD: Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa'). Cancer Lett 202: 43-51, 2003.
49. Sundberg AL, Almqvist Y, Tolmachev V and Carlsson J: Treatment of cultured glioma cells with the EGFR-TKI gefitinib ('Iressa', ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition. Eur J Nucl Med Mol Imaging 30: 727-729, 2003.
50. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE II, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD and Friedman HS: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22: 133-142, 2004.
51. Li B, Chang CM, Yuan M, McKenna WG and Shu HK: Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 63: 7443-7450, 2003.
52. Lammering G, Hewit TH, Valerie K, Lin PS, Contessa JN and Schmidt-Ullrich RK: Anti-erbB receptor strategy as a gene therapeutic intervention to improve radiotherapy in malignant human tumours. Int J Radiat Biol 79: 561-568, 2003.
53. Nagy P, Arndt-Jovin DJ and Jovin TM: Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells. Exp Cell Res 285: 39-49, 2003.
54. Zhang M, Zhang X, Bai CX, Chen J and Wei MQ: Inhibition of epidermal growth factor receptor expression by RNA interference in A549 cells. Acta Pharmacol Sin 25: 61-67, 2004.
55. Dancey J: Epidermal growth factor receptor inhibitors in clinical development. Int J Radiat Oncol Biol Phys 58: 1003-1007, 2004.
56. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
57. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
58. A Chakravarti A, Seiferheld W, Tu X, Wang H, Chang H, Ang K, Hammond E, Curran W, Mehta M Jr: Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 62: 318-327, 2005.